BACKGROUND: Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy. METHODS: We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1, or no additional clinical benefit. The two primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat population. RESULTS: A total of 201 patients were randomly assigned to the atezolizumab group, and 202 patients to the placebo group. At a median follow-up of 13.9 months, the median overall survival was 12.3 months in the atezolizumab group and 10.3 months in the placebo group (hazard ratio for death, 0.70; 95% confidence interval [CI], 0.54 to 0.91; P=0.007). The median progression-free survival was 5.2 months and 4.3 months, respectively (hazard ratio for disease progression or death, 0.77; 95% CI, 0.62 to 0.96; P=0.02). The safety profile of atezolizumab plus carboplatin and etoposide was consistent with the previously reported safety profile of the individual agents, with no new findings observed. CONCLUSIONS: The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann-La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579 .).

From Vanderbilt University Medical Center

Komentář v

Nat Rev Clin Oncol. 2018 Dec;15(12):725. doi: 10.1038/s41571-018-0109-9. PubMed

Komentář v

Cancer Discov. 2018 Dec;8(12):OF10. doi: 10.1158/2159-8290.CD-NB2018-133. PubMed

Komentář v

Ann Transl Med. 2018 Dec;6(Suppl 2):S120. doi: 10.21037/atm.2018.12.25. PubMed

Komentář v

N Engl J Med. 2019 Feb 28;380(9):888-889. doi: 10.1056/NEJMc1900123. PubMed

Komentář v

N Engl J Med. 2019 Feb 28;380(9):889. doi: 10.1056/NEJMc1900123. PubMed

Komentář v

N Engl J Med. 2019 Feb 28;380(9):889-890. doi: 10.1056/NEJMc1900123. PubMed

Citace poskytuje Crossref.org

Comparison of the efficacy of cisplatin and carboplatin in combination with etoposide in firstline treatment of extensive-stage small cell lung cancer in real-world practice in the Czech Republic - a retrospective analysis of patients from the LUCAS project

Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden

Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Zobrazit více v PubMed

ClinicalTrials.gov
NCT02763579